Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

33 Results

Guidelines and Advice

Sorafenib for Advanced Hepatocellular Carcinoma

Status: Archived
ID: CED 7

Feb 2008

Guidelines and Advice

Bevacizumab for Recurrent Glioblastoma Multiforme (GBM)

Status: Archived
ID: CED 19

Jul 2010

Guidelines and Advice

Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Status: Current
ID: GL 4-1
Version: 2

Jan 2021

Guidelines and Advice

Dose-intensive Chemotherapy with Growth Factor or Autologous Bone Marrow/Stem Cell Transplant Support in Advanced or Metastatic Adult Soft Tissue Sarcoma

Status: Archived
ID: 11-5

Sep 2011

Guidelines and Advice

Sunitinib Malate for Gastrointestinal Stromal Tumour (GIST) in Imatinib Mesylate Resistant Patients

Status: Archived
ID: 11-8
Version: 2

Oct 2015

Guidelines and Advice

Position Statements for the Implementation of Oncology Biosimilars from the pan-Canadian Clinical Operations Working Group

Status: Current
Version: 1

Aug 2019

Guidelines and Advice

Management of Cancer Medication-Related Infusion Reactions

Status: Current
Version: 1

Aug 2019

Guidelines and Advice

Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Status: Current
ID: GL 4-18
Version: N/A

Sep 2020

Guidelines and Advice

Systemic therapy of denosumab in altering surgical outcomes in patients with giant cell tumour of bone

Status: Current
ID: ES 11-13

Feb 2021

Pages